Several cardiovascular risk factors, such as advanced age and smoking history, are prevalent among lung cancer patients at ...

New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.

Unlike the other more well-known type of liver cancer, hepatocellular carcinoma ... As he was admitted to a liver ward for a ...

T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new study. Researchers at Karolinska Institutet have investigated how immune cells ...

A multicenter prospective study to evaluate the efficacy of resection for initially unresectable hepatocellular carcinoma after atezolizumab combined with bevacizumab (the RACB study): Short-term ...

A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child–Pugh class B cirrhosis: CHALLENGE ...

The median progression-free survival per RECICL was 10.8 months in the combination arm and 3.2 months in the TACE-alone arm. Adding camrelizumab and rivoceranib to transarterial chemoembolization ...

1Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, Hammersmith Hospital, London, United Kingdom. 2Department of Translational Medicine (DIMET), University of Piemonte ...

aDepartment of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China bDepartment of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China ...

“The casdozo data in HCC demonstrate translation of the preclinical data in liver cancer to first-line HCC cancer patients with efficacy and a favorable safety profile. These data support the ...